Renaissance Pharma Acquires Denavir Assets

Renaissance Pharma has acquired certain assets and the U.S. rights to manufacture, market and sell Denavir  (1% penciclovir cream), from Deerfield Management Co. and New American Therapeutics, a Deerfield portfolio company. Denavir is a topical antiviral for the treatment of recurrent cold sores. 
 
With the acquisition of Denavir, Renaissance has established a new subsidiary, Prestium Pharma, focused on commercializing branded products in the U.S. John Denman will serve as general manager of Prestium. Mr. Denman has more than 25 years of experience. Before joining the company, he held positions of increasing responsibility at Teva Pharmaceuticals and most recently was responsible for all aspects of its U.S. commercial operations including sales, marketing, R&D, and business development. Prior to Teva, Mr. Denman held a senior marketing position at Sandoz.
 
Pierre Frechette, president and chief executive officer of Renaissance, said, “We are enthusiastic about the acquisition of our first branded product and the creation of Prestium, and look forward to further expanding our product portfolio.”